You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

 

177 Results
Document
Document
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal, 
Small bowel and appendix
Intent: Palliative
Funding:
New Drug Funding Program
    Bevacizumab (Biosimilar) - Metastatic Colorectal, Small Bowel, or Appendiceal Cancer
Nov 2023
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal, 
Small bowel and appendix
Intent: Palliative
Nov 2023
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Intermediate Grade
Intent: Curative
Regimen
Cancer Type:
Hematologic, 
Lymphoma - T-cell
Intent: Palliative
Funding:
New Drug Funding Program
    Mogamulizumab - Relapsed or Refractory Mycosis Fungoides or Sezary Syndrome
Regimen
Cancer Type:
Hematologic, 
Leukemia - Chronic Lymphocytic (CLL)
Intent: Palliative
Funding:
Exceptional Access Program
    zanubrutinib - For the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) who have received at least one prior therapy; and for the treatment of adult patients with previously untreated CLL.
Mar 2024

Pages